High Comorbidity Burden in Resistant, Refractory Migraine Vs Chronic Migraine
Drug Topics
DECEMBER 17, 2024
Treatment of comorbidities may help patients overcome resistance or refractoriness to migraine therapies.
Tue.Dec 17, 2024
446 
Does Mounjaro need to be refrigerated?
The Checkup by Singlecare
DECEMBER 17, 2024
Like semaglutide, Mounjaro (tirzepatide) is a once-a-week injectable medication that is FDA approved for helping manage blood sugar levels in those with Type 2 diabetes. It mimics two gastrointestinal hormones: glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). So, the active ingredient can also be prescribed for weight loss or obesity, combined with diet and exercise, under its licensed brand name Zepbound.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
A biotech’s race to tackle the most severe hepatitis
PharmaVoice
DECEMBER 17, 2024
Bluejay Therapeutics is one of just a handful of companies developing treatments for hepatitis D.
Wearing CGMs Can Help Student Pharmacists Improve Counseling Ability
Drug Topics
DECEMBER 17, 2024
Student pharmacists who wore a continuous glucose monitor had a higher average counseling score during an encounter with a patient and a higher overall confidence score.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT+: PBMs face scrutiny from all sides, and analyzing Marty Makary’s road to the FDA
STAT
DECEMBER 17, 2024
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Congress nears spending deal with long-awaited PBM reforms Congress is on the edge of a deal that would reshape pharmacy benefit managers, extend telehealth access, and renew certain public health authorities.
Q&A: Pharmacist’s Perspective on How Biosimilars Will Impact the Field in the Coming Years
Drug Topics
DECEMBER 17, 2024
A conversation with Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at the Mayo Clinic.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Triptans Associated With Adverse Events Across Organ Systems
Drug Topics
DECEMBER 17, 2024
Triptans are used to treat acute migraine and cluster headaches.
Men With History of Cannabis Use Have Less Cognitive Decline From Early Adulthood to Late Midlife
Pharmacy Times
DECEMBER 17, 2024
The investigators also find that age of initiation and frequent use were not associated with a greater age-related cognitive decline.
Q&A: How Pharmacists Can Help Patients with COPD, Inhaler Misuse | ASHP Midyear
Drug Topics
DECEMBER 17, 2024
Drug Topics met with Lourdes Cross, PharmD, BCACP, CDCES, to discuss pharmacists role in managing patients chronic obstructive pulmonary disease.
Paxlovid’s Double-Edged Sword: Treating COVID-19 and the Risk of Viral Load Rebound
Pharmacy Times
DECEMBER 17, 2024
The conversation of VLR has sparked a discussion as to whether or not other COVID-19 treatment agents are associated with a surge in symptoms and if so, how those agents compare with the rebound effect of nirmatrelvir/ritonavir.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Maternal mortality trends remain dire — and researchers face an uphill battle to solve them
PharmaVoice
DECEMBER 17, 2024
Rising maternal mortality, particularly among vulnerable populations, stems in part from a lack of research in pregnant women.
CMS sunsets Medicare Advantage value-based model, citing billions in costs
Fierce Healthcare
DECEMBER 17, 2024
The Centers for Medicare & Medicaid Services (CMS) is discontinuing the Medicare Advantage (MA) Value-Based Insurance Design model at the end of 2025. | The Value-Based Insurance Design model for Medicare Advantage plans will be terminated at the end of next year.
STAT+: FDA deputy commissioner Namandjé Bumpus to leave agency
STAT
DECEMBER 17, 2024
Namandjé Bumpus, principal deputy commissioner of the Food and Drug Administration, is leaving the agency. Commissioner Robert Califf shared the news with staff Tuesday morning, according to an email reviewed by STAT.
Nuclear Isotopes Could Help Address Challenges in Oncology Clinical Trials
Pharmacy Times
DECEMBER 17, 2024
The radiation emerging from these isotopes can be used in 2 different ways in cancer trials: imaging (detection of tumors) and therapy (destruction of tumors).
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Novo Nordisk invests $1.2bn in new Denmark facility
Pharmaceutical Technology
DECEMBER 17, 2024
Construction has already begun on the Ozempic-producers new Denmark production facility and 40,000m2 warehouse.
2025 outlook: Employers face yet another year of healthcare cost increases
Fierce Healthcare
DECEMBER 17, 2024
Employers are bracing for healthcare costs to spike yet again in 2025, and that's likely to push these firms to pursue significant changes, experts said. | Employers are bracing for healthcare costs to spike yet again in 2025, and that's likely to push these firms to pursue significant changes, experts said.
FDA rejects J&J's subcutaneous Rybrevant filing and AZ's full approval bid for Andexxa
Fierce Pharma
DECEMBER 17, 2024
Johnson & Johnson has received coal in its stocking from the FDA as manufacturing issues have tripped up the companys attempt to gain approval of its subcutaneous version of lung cancer drug R | The FDA has sent complete response letters to Johnson & Johnson and AstraZeneca, rejecting J&J's application for subcutaneous Rybrevant and AZ's bid for a full approval of Andexxa.
FDA Approves Crinecerfont for Adult, Pediatric Patients with Congenital Adrenal Hyperplasia
Pharmacy Times
DECEMBER 17, 2024
The decision is based on positive results from the CAHtalyst trials, which both met their primary and secondary end points.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Teva, Sanofi score well with anti-TL1A drug in IBD test
pharmaphorum
DECEMBER 17, 2024
Phase 2b results with Sanofi and Teva's duvakitug are exciting and warrant a swift move to phase 3 in inflammatory bowel disease, say the companies.
AbbVie acquires Roche immune drug spinout in $200 million deal
Outsourcing Pharma
DECEMBER 17, 2024
AbbVie acquires Nimble Therapeutics in $200M deal to advance oral peptide therapies for autoimmune diseases.
Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025
Fierce Pharma
DECEMBER 17, 2024
After pulling off a surprise third-quarter beat and full-year guidance raise amid shareholder activism earlier this year, Pfizer now expects its 2025 revenues to come in the same range as in 2024.< | After pulling off a surprise third-quarter beat and full-year guidance raise amid shareholder activism earlier this year, Pfizer now expects its 2025 revenues to come in the same range as in 2024.
Study backs Closed Loop's drug+digital blood pressure plan
pharmaphorum
DECEMBER 17, 2024
Closed Loop Medicine's smartphone app for blood pressure monitoring has shown proof-of-concept in the Cure-19 study.
Regeneron's Eylea HD passes key test in retinal vein occlusion, teeing up 2025 FDA filing as Eylea threats mount
Fierce Pharma
DECEMBER 17, 2024
With Eylea biosimilar competition creeping in and Roches Vabsymo jockeying for market share in key indications, Regeneron is racing to carve out a new market for the high-dose version of its block | High-dose Eylea demonstrated non-inferiority to the original version of the drug in patients with macular edema following retinal vein occlusion, an indication Eylea has held for a decade.
ASH 2024: Nuvisertib Demonstrates Durable Response in Relapsed/Refractory Myelofibrosis
Pharmacy Times
DECEMBER 17, 2024
Firas El Chaer, MD, discusses newly-presented data at ASH demonstrating nuvisertib's effectiveness in myelofibrosis.
CTO Europe 2024: keep the burden of trials away from patients, say experts
Pharmaceutical Technology
DECEMBER 17, 2024
The two-day event included talks on subjects ranging from how to best utilise AI to how to build a stable CRO.
Camber Pharmaceuticals Announces Addition of Erlotinib Tablets
Pharmacy Times
DECEMBER 17, 2024
Erlotinib Tablets are available in 25 mg, 100 mg, and 150 mg strengths, packaged in 30-count bottles.
2025 outlook: What's next for AI scribes and virtual care
Fierce Healthcare
DECEMBER 17, 2024
In 2025, the healthcare industry will expect more out of artificial intelligence. | Fierce Healthcare interviewed nine executives on what the AI scribe and telehealth markets will look like in 2025. Executives expect AI companies to consolidate and for virtual care to latch onto the momentum of the technology to transform care.
Pathways to Improve Overall Survival in Myelofibrosis: Finding Alternate Trial End Points
Pharmacy Times
DECEMBER 17, 2024
Measuring end points such as molecular response, cytokines, and histomorphometry may show a greater range of benefits.
China NMPA approves MSD’s KEYTRUDA for stages of NSCLC
Pharmaceutical Technology
DECEMBER 17, 2024
China National Medical Products Administration (NMPA) has approved MSDs KEYTRUDA for treating certain non-small cell lung cancer (NSCLC).
ASHP Midyear: Pharmacist Emphasizes Individualized Approach to Antiplatelet Therapy Management
Pharmacy Times
DECEMBER 17, 2024
Snehal Bhatt discusess the need to individualize antiplatelet therapy decisions based on a comprehensive assessment of each patient's unique risk factors for thrombosis and bleeding.
Biotech bounces back as venture funding grows $3.8m from 2023 to 2024YTD
Pharmaceutical Technology
DECEMBER 17, 2024
However, caution persists:166 of 785 US venture-backed companies with an innovator drug in development have not raised capital since 2021.
Study Finds Asthma Is Common Among Children With Primary Ciliary Dyskinesia
Pharmacy Times
DECEMBER 17, 2024
The authors note that routine screening in patients with primary ciliary dyskinesia to help identify undiagnosed asthma.
GSK’s lung cancer therapy gains EMA PRIME designation
Pharmaceutical Technology
DECEMBER 17, 2024
GSKs GSK227 has gained Priority Medicines (PRIME) designation from the EMA for the treatment of relapsed ES-SCLC.
Let's personalize your content